Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

ek 26 with Bronchitol (p=0.001). Again, there was an immediate and sustained improvement in FEV1 over the 26 week period of the study (p=0.003). -- While the study was not powered to show a reduction in the secondary endpoint of exacerbation, the rate of a protocol defined pulmonary exacerbation (PDPE) per subject for the 26 weeks was lower for Bronchitol versus control: overall reduction in rate of 25% (p=0.2). -- There was a non significant increase in time to first PDPE (p=0.1) for the Intention to Treat group, however, for the Per Protocol population, i.e. those who were mostly compliant with therapy and stayed in the study, there was a significant increase in time to first PDPE (p=0.026). -- There was a clinically meaningful change from baseline (129mL) and control (113mL) at week 26 with Bronchitol for Forced Vital Capacity (FVC) of the lung (p=0.002). Additionally, treatment with Bronchitol showed an immediate and sustained improvement in lung capacity (FVC) over the 26 week treatment period (p<0.001). Safety -- There was a similar number of adverse events and serious adverse events per treatment group, with no deaths in the study. -- Respiratory adverse events that were more common with Bronchitol compared with placebo, included cough (25.4% versus 20.3%), haemoptysis (11.9% versus 8.5%) and pharyngolaryngeal pain (13.6% versus 4.2%). -- There were similar rates between the groups for adverse events of particular interest including: wheezing, asthma, bronchospasm (Bronchitol 4.5% versus 5.9%). -- At screening 7% of patients were ineligible to participate due to suspected undiagnosed hyperreactive airway disease. -- Overall infections were lower in the Bronchitol group (39% versus 47.5%). -- There was no difference in microbial growth for specifi
'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Involution Studios , ... of a new infographic, Understanding Ebola . ... beautifully designed, easy to follow informative tool for anyone ... outbreak, symptoms and prevention. , "As the news has ... 2014 Ebola outbreak represents not only a healthcare crisis ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... , -- Leading Movement Disorder Experts and ... for all Ages and Stages of the Disease -- , ... more than 1.5 million Americans living with Parkinson,s disease, the importance ... on key topics that impact the quality of daily living with ...
... , MISSISSAUGA, ON , Feb. 11 /PRNewswire-FirstCall/ ... on its JAK1/2 inhibiting small molecule (CYT387) and on its novel ... Lorne , Victoria, Australia . CYT387 is an oral JAK1/2 ... by Dr. Andrew Wilks , the founder of Cytopia Limited, ...
... , WASHINGTON , Feb. 10 Dr. ... recipient of the nation,s highest scientific honors, will address the National ... of his talk will be "A New Era of Quantum Leaps ... postponed because of snow. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080917/NPCLOGO ) , ...
Cached Biology Technology:Davis Phinney Foundation Launches 'Every Victory Counts' Program to Inform and Empower People to Live Well With Parkinson's 2Davis Phinney Foundation Launches 'Every Victory Counts' Program to Inform and Empower People to Live Well With Parkinson's 3Davis Phinney Foundation Launches 'Every Victory Counts' Program to Inform and Empower People to Live Well With Parkinson's 4Davis Phinney Foundation Launches 'Every Victory Counts' Program to Inform and Empower People to Live Well With Parkinson's 5YM BioSciences presents CYT387 and CYT997 data at international cancer conference 2YM BioSciences presents CYT387 and CYT997 data at international cancer conference 3YM BioSciences presents CYT387 and CYT997 data at international cancer conference 4NIH Director Francis Collins to Speak at National Press Club February 26 on 'A New Era of Quantum Leaps in Biomedical Research' 2NIH Director Francis Collins to Speak at National Press Club February 26 on 'A New Era of Quantum Leaps in Biomedical Research' 3
(Date:10/14/2014)... is how to produce enough food to feed the ... Agriculture Organization of the United Nations predicts that food ... to feed a growing global population, and plants are ... production. Plants—grains, cereals, fruits, vegetables, and more—feed humans ... must tap into our knowledge of how plants work ...
(Date:10/14/2014)... Montreal, October 14, 2014 – High doses of fish oil ... fibrillation, a common type of irregular heartbeat in which the ... The results of the AFFORD trial led by the Montreal ... American College of Cardiology on October 7th. , For ... antiarrhythmic therapy were randomly assigned to 4 grams of fish ...
(Date:10/14/2014)... – A team of scientists led by researchers ... and the University of Miami Miller School of ... key genetic pathway underlying bipolar (manic depressive) disorder, ... for treating bipolar affective disorder, as well as ... new findings, published online this week in Nature ...
Breaking Biology News(10 mins):Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... aging and many age-related diseases is oxidative stress," says the ... of pathology. The skin of a bitten apple will brown ... that is a good metaphor for the damage that oxidative ... over time. , Humans and other organisms depend on oxygen ...
... Avoiding quicksand along the banks of the Ivindo River in ... patterns of electricity created by fish in the water. ... groups of local electric fish have different DNA, different communication ... have found a case where two types of electric signals ...
... Using a "clot buster" drug normally reserved for treating patients ... double the number of patients who could be revived from ... more than 260,000 people a year nationwide ?and at least ... as a new therapy for this abrupt and catastrophic loss ...
Cached Biology News:Free radical cell death switch identified 2Electric fish in Africa could be example of evolution in action 2Clot-busting drug helps revive cardiac arrest patients 2
... an aqueous solution that contains a purified ... in a saline solution, pH 6.5 ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ... and stabilizer for biologically active components in ...
... and clarification reagent; Ideal for clarifying ... antibodies, proteins, nucleic acids, & proteoglycans; ... and improves downstream processing; Utilizes a ... adsorbent supplied as a suspension in ...
... Biomolecule Stabilizer is a bovine protein-free alternative ... an aqueous solution that contains non-toxic chemicals ... pH 6.6 - 7.2, and does not ... the activity of antibodies and other biomolecules ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
Biology Products: